FDA Approves Levoleucovorin for Injection for mCRC, Osteosarcoma

On October 23, the FDA approved levoleucovorin for injection (Khapzory, Spectrum Pharmaceuticals, Inc.) for three indications:

• Rescue after high-dose methotrexate therapy in patients with osteosarcoma
• Diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination
• The treatment of patients with metastatic colorectal cancer (mCRC) in combination with fluorouracil.

Read the Spectrum Pharmaceuticals press release here.